UNSPSC 51373336: Buprenorphine/naloxone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373336 Buprenorphine/naloxone is a Commodity code that state and local governments procure to support overdose-reversal and substance-use disorder treatment programs. The code encompasses opioid antagonists and medication-assisted treatment products, though recent solicitations reveal that state and local buyers are procuring these products both as standalone items and as components of broader community health initiatives that include related drug-deactivation and pharmaceutical-supply infrastructure. Issuing bodies range from county health departments to state health commissions and multistate cooperative purchasing alliances. Seminole County, Florida, for example, procures naloxone and drug deactivation systems through annual standing contracts to support community health delivery, while the Texas Health and Human Services Commission is exploring direct-to-manufacturer pharmacy models that would encompass buprenorphine/naloxone products as part of broader prescription fulfillment optimization. Multistate cooperatives like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) also solicit generic pharmaceuticals, including products in this family, on behalf of participating state and local health systems across multiple jurisdictions.

The code shows recent activity in Florida and Texas, with MMCAP's multistate framework extending procurement reach across Minnesota, Oregon, and other participating states. Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly delivery to the Seminole County Community Health Building in Sanford, Florida; and the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs that would include products in this category. The MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals, posted January 20, 2026 with a March 26, 2026 response deadline, reflects the cooperative purchasing model used across state and local jurisdictions, requiring vendors to supply through authorized wholesalers and maintain compliance with cGMP and Drug Supply Chain Security Act standards.